SK Bioscience Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
1,085
- Stock Symbol
-
302440
- Investments
-
6
- Share Price
-
$29.51
- (As of Thursday Closing)
SK Bioscience General Information
Description
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and development of vaccines. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further, it has several other vaccines under development and clinical trials, including a recombinant rotavirus vaccine.
Contact Information
Website
www.skbioscience.comCorporate Office
- 38, Yeongudanjeong-ro
- Incheon, Yeonsu 13494
- South Korea
Corporate Office
- 38, Yeongudanjeong-ro
- Incheon, Yeonsu 13494
- South Korea
SK Bioscience Timeline
SK Bioscience Stock Performance
As of 12-Nov-2026, SK Bioscience’s stock price is $29.51. Its current market cap is $2.32B with 78.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $29.51 | $29.75 | $21.85 - $38.43 | $2.32B | 78.5M | 88.1K | -$0.74 |
SK Bioscience Financials Summary
As of 30-Jun-2026, SK Bioscience has a trailing 12-month revenue of $454M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,753,361 | 2,382,750 | 1,908,000 | 3,339,035 |
| Revenue | 454,274 | 457,699 | 196,085 | 282,616 |
| EBITDA | (5,377) | (786) | (31,643) | 22,896 |
| Net Income | (58,362) | (40,351) | (39,490) | 17,070 |
| Total Assets | 1,932,452 | 2,052,587 | 1,930,517 | 1,437,471 |
| Total Debt | 352,147 | 326,378 | 266,681 | 15,965 |
SK Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SK Bioscience Comparisons
Industry
Financing
Details
SK Bioscience Competitors (2)
One of SK Bioscience’s 2 competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA | ||||
| Codagenix | Venture Capital-Backed | Farmingdale, NY |
SK Bioscience Patents
SK Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026225993-A1 | Oncolytic virus and pharmaceutical composition for preventing or treating triple-negative breast cancer comprising same | Pending | 23-Apr-2025 | ||
| WO-2026155604-A1 | Nucleic acid molecule for reducing size or volume of target tissue containing adipocytes, composition containing same, or use thereof for reducing adipocytes | Pending | 17-Jan-2025 | ||
| US-20250281594-A1 | Truncated recombinant l1 protein of human papillomavirus | Pending | 11-Mar-2024 | ||
| WO-2025192967-A1 | Truncated recombinant l1 protein of human papillomavirus | Pending | 11-Mar-2024 | ||
| EP-4825867-A1 | Mutant rsv protein | Pending | 15-Dec-2023 | C07K14/005 |
SK Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SK Bioscience Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SK Bioscience Investments & Acquisitions (6)
SK Bioscience’s most recent deal was a Later Stage VC with Sunflower Therapeutics for . The deal was made on 03-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sunflower Therapeutics | 03-Dec-2024 | Later Stage VC | Discovery Tools (Healthcare) | ||
| Fina Biosolutions | 08-Oct-2024 | Corporate | Drug Discovery | ||
| IDT Biologika | 01-Oct-2024 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Novavax | 08-Aug-2023 | PIPE | Pharmaceuticals | ||
| CTCELLS | 22-Mar-2022 | Early Stage VC | Diagnostic Equipment |
SK Bioscience ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
19.44 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
SK Bioscience Exits (1)
SK Bioscience’s most recent exit was on 08-Aug-2023 from Novavax. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Novavax | 08-Aug-2023 | Completed |
|
SK Bioscience Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| IDT Biologika | Dessau-Rosslau, Germany | 1921 |
SK Bioscience FAQs
-
When was SK Bioscience founded?
SK Bioscience was founded in 2001.
-
Where is SK Bioscience headquartered?
SK Bioscience is headquartered in Incheon, South Korea.
-
What is the size of SK Bioscience?
SK Bioscience has 1,085 total employees.
-
What industry is SK Bioscience in?
SK Bioscience’s primary industry is Drug Discovery.
-
Is SK Bioscience a private or public company?
SK Bioscience is a Public company.
-
What is SK Bioscience’s stock symbol?
The ticker symbol for SK Bioscience is 302440.
-
What is the current stock price of SK Bioscience?
As of 12-Nov-2026 the stock price of SK Bioscience is $29.51.
-
What is the current market cap of SK Bioscience?
The current market capitalization of SK Bioscience is $2.32B.
-
What is SK Bioscience’s current revenue?
The trailing twelve month revenue for SK Bioscience is $454M.
-
Who are SK Bioscience’s competitors?
CytoAgents and Codagenix are competitors of SK Bioscience.
-
What is SK Bioscience’s annual earnings per share (EPS)?
SK Bioscience’s EPS for 12 months was -$0.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
